Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 223.0% in July
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 223.0% in July
Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 612,400 shares, a growth of 223.0% from the June 30th total of 189,600 shares. Based on an average daily trading volume, of 706,600 shares, the days-to-cover ratio is presently 0.9 days.
埃斯隆医疗公司(纳斯达克：AEMD-GET评级)是7月份空头股数业务大幅增长的接受者。截至7月15日，空头股数共有612,400股，较6月30日的189,600股增长223.0%。以日均成交量706,600股计算，目前天数与回补比率为0.9天。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, StockNews.com began coverage on shares of Aethlon Medical in a research note on Saturday, July 16th. They set a "sell" rating on the stock.
另外，StockNews.com在7月16日星期六的一份研究报告中开始报道Aethlon Medical的股票。他们对该股设定了“卖出”评级。
Institutional Trading of Aethlon Medical
爱思强医疗的制度性交易
An institutional investor recently bought a new position in Aethlon Medical stock. NTB Financial Corp acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,425 shares of the medical equipment provider's stock, valued at approximately $32,000. NTB Financial Corp owned 0.11% of Aethlon Medical at the end of the most recent reporting period. Institutional investors own 10.58% of the company's stock.
一家机构投资者最近买入了Aethlon Medical股票的新头寸。根据NTB金融公司最近向美国证券交易委员会提交的13F文件，该公司在第四季度收购了埃斯隆医疗公司(纳斯达克代码：AEMD-GET Rating)的新股份。该机构投资者购买了这家医疗设备供应商的17,425股股票，价值约32,000美元。在最近的报告期结束时，NTB金融公司拥有Aethlon Medical 0.11%的股份。机构投资者持有该公司10.58%的股票。
Aethlon Medical Price Performance
艾司朗医疗价格表现
Aethlon Medical Company Profile
艾斯隆医疗公司简介
(Get Rating)
(获取评级)
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
Aethlon Medical，Inc.是一家医疗技术公司，专注于开发在美国诊断和治疗危及生命和器官的疾病的产品。该公司开发艾司朗血液净化器，这是一种临床阶段的免疫治疗设备，可以从人类循环系统中移除肿瘤衍生的外小体和威胁生命的病毒，包括移除新冠肺炎病毒、相关变异体和相关的外小体。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
- Consumer Staple Kraft-Heinz Quietly Builds Momentum
- Steady, Stable Kimberly-Clark Yields 3.4%
- 免费获取StockNews.com关于Aethlon Medical(AEMD)的研究报告
- 尽管季度亏损，但Shopify股市反弹
- 两家机构正在购买的两只自动化股票
- 欧文斯-康宁能隔离你的投资组合吗？
- 消费品卡夫-亨氏悄然形成势头
- 稳定，稳定的金佰利收益率为3.4%
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《艾斯龙医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aethlon Medical和相关公司的最新新闻和分析师评级的每日简要摘要。